These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27505709)

  • 41. A novel human anti-BAFF neutralizing monoclonal antibody derived from in vitro immunization.
    Tong Y; Zhong S; Shan Z; Yao W; Tian H
    Biomed Pharmacother; 2019 Nov; 119():109430. PubMed ID: 31518874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors.
    Shiung YY; Chiang CY; Chen JB; Wu PC; Hung AF; Lu DC; Pan RL; Chang TW
    Immunobiology; 2012 Jul; 217(7):676-83. PubMed ID: 22226669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BLyS levels in sera of patients with systemic lupus erythematosus: clinical and serological correlation.
    Elbirt D; Asher I; Mahlab-Guri K; Bezalel-Rosenberg S; Edelstein V; Sthoeger Z
    Isr Med Assoc J; 2014 Aug; 16(8):491-6. PubMed ID: 25269340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. B cell targeted therapies in autoimmune diseases.
    Isenberg DA
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors.
    Jacob CO; Yu N; Sindhava V; Cancro MP; Pawar RD; Putterman C; Stohl W
    Arthritis Rheumatol; 2015 Sep; 67(9):2523-35. PubMed ID: 25989238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.
    Stohl W; Scholz JL; Cancro MP
    Curr Opin Rheumatol; 2011 May; 23(3):305-10. PubMed ID: 21330926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The BLyS family: toward a molecular understanding of B cell homeostasis.
    Treml JF; Hao Y; Stadanlick JE; Cancro MP
    Cell Biochem Biophys; 2009; 53(1):1-16. PubMed ID: 19034695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activation of LXR attenuates collagen-induced arthritis via suppressing BLyS production.
    Huang Y; Fu X; Lyu X; Xu Z; He Z; Zhang Y; Zeng Y; He F; Huang G
    Clin Immunol; 2015 Dec; 161(2):339-47. PubMed ID: 26431776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
    Dörner T
    J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel BLyS antagonist peptide designed based on the 3-D complex structure of BCMA and BLyS.
    Sun J; Feng J; Li Y; Shen B
    Biochem Biophys Res Commun; 2006 Aug; 346(4):1158-62. PubMed ID: 16793005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.
    Kadavath S; Bobic S; Efthimiou P
    Clin Rheumatol; 2015 Sep; 34(9):1651-2. PubMed ID: 25652332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A therapeutic role for BLyS antagonists.
    Stohl W
    Lupus; 2004; 13(5):317-22. PubMed ID: 15230285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.
    Stohl W
    Curr Dir Autoimmun; 2005; 8():289-304. PubMed ID: 15564726
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and release of B-lymphocyte stimulator from myeloid cells.
    Nardelli B; Belvedere O; Roschke V; Moore PA; Olsen HS; Migone TS; Sosnovtseva S; Carrell JA; Feng P; Giri JG; Hilbert DM
    Blood; 2001 Jan; 97(1):198-204. PubMed ID: 11133761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination.
    Yamada T; Zhang K; Yamada A; Zhu D; Saxon A
    Am J Respir Cell Mol Biol; 2005 May; 32(5):388-94. PubMed ID: 15668322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.
    Quartuccio L; Salvin S; Fabris M; Maset M; Pontarini E; Isola M; De Vita S
    Rheumatology (Oxford); 2013 Feb; 52(2):276-81. PubMed ID: 22879463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.
    Bishton M; Spencer A; Dickinson M; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):575-8. PubMed ID: 23773449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.